Lighting the Way to Early Cancer Detection
Non-invasive
tests
Patented
clinically validated
Accurate
affordable
Early
detection
About Us
About Us
Procyon Diagnostics is a new spin out company from Queen Mary University of London (QMUL). The aim of the company is to help commercialise clinical biomarker technology arising from QMUL research and development.
Procyon utilises advanced biomarker technologies with algorithmic and machine learning analysis and aims to become a leading provider of new precision assays for early cancer detection, primarily based on primarily based on body fluids such as blood and urine.
Our Aims
Non-invasive, simple tests for the early detection of single cancer
Using patented and clinically validated technologies
Fast turnarounds for patient results
Accurate and affordable tests
Early detection means more successful clinical intervention and better chance of survival
